Business Wire

Chugai's Bispecific Antibody Emicizumab Meets Primary Endpoint in Phase lll Study

Del

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the primary endpoint has been met for the global phase lll HAVEN 3 (NCT02847637) study evaluating emicizumab (ACE910) subcutaneous injection, once a week and once every two weeks, in patients with hemophilia A (12 years of age or older) without inhibitors to factor Vlll. A statistically significant reduction in the number of bleeds was confirmed in patients treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment. The study also met a secondary endpoint that once-weekly emicizumab prophylaxis was superior to factor VIII prophylaxis, as demonstrated by a statistically significant and clinically meaningful reduction in treated bleeds in an intra-patient comparison of patients receiving emicizumab prophylaxis compared to their prior factor VIII prophylaxis. The most common adverse events with emicizumab were injection site reactions, consistent with prior studies. No thrombotic events occurred in this study. Further details will be presented at a future medical meeting.

“Prophylactic factor VIII replacement therapy is a standard treatment for hemophilia A patients without inhibitors. However, some patients and their caregivers have difficulties with the frequent intravenous injections in their daily life,” said Chugai’s Senior Vice President, Head of Project & Lifecycle Management Unit, Dr. Yasushi Ito. “As a subcutaneous injection, emicizumab can be administered more easily. Today’s results, which are consistent with data reported from patients with inhibitors earlier this year, showed that emicizumab may have the potential to become an efficacious treatment option for hemophilia A patients without inhibitors. We expect emicizumab to provide benefits to a wide range of patients with hemophilia A.”

Emicizumab is an investigational bispecific monoclonal antibody, which was developed using Chugai’s proprietary antibody engineering technologies. The drug is designed to bind factor lXa and factor X. In doing so, emicizumab provides the cofactor function of factor Vlll in people with hemophilia A, who either lack or have impaired coagulation function of factor Vlll1,2). In November this year, the drug (US product name: HEMLIBRA®; Genentech) was approved by the U.S. Food and Drug Administration “for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors”. An EU marketing authorization application was submitted in June 2017 and is being reviewed under Accelerated Assessment by the European Medicines Agency. In Japan, emicizumab obtained an orphan drug designation in August 2016 from the Ministry of Health, Labour and Welfare for the prevention and reduction of bleeding episodes in patients with congenital FVIIl deficiency (hemophilia A) who developed inhibitors to FVIII, followed by an application for regulatory approval filed in July 2017.

About HAVEN 3 study (NCT02847637)

HAVEN 3 study is a randomized, multicentre, open-label phase lll study evaluating the efficacy, safety and pharmacokinetics of emicizumab prophylaxis subcutaneous injection once a week and once every two weeks. The study enrolled 152 patients with hemophilia A, 12 years of age or older without inhibitors to factor Vlll, who were previously treated with episodic or prophylactic factor Vlll therapy. The primary endpoint of the study is the number of bleeds over time with emicizumab prophylaxis (Arm A and Arm B) versus no prophylaxis (Arm C). Secondary endpoints include joint bleed rate, target joint bleed rate, health-related quality of life (HRQoL)/ health status, intra-patient comparison to bleed rate on their prior prophylaxis regimen with factor Vlll therapy (Arm D) and safety.

 

[Study Design]

Patients previously treated with episodic factor Vlll therapy were randomized in a 2:2:1 fashion to either Arm A, B or C.

Arm A
(n=34)

        Received emicizumab prophylaxis at 3mg/kg by once-weekly subcutaneous injection for 4 weeks, followed by 1.5 mg/kg once-weekly subcutaneous injection

Arm B
(n=34)

      Received emicizumab prophylaxis at 3mg/kg by once-weekly subcutaneous injection for 4 weeks, followed by 3 mg/kg once every two weeks subcutaneous injection

Arm C
(n=17)

        No prophylaxis control arm
 

Patients previously treated with factor Vlll prophylactic were enrolled in:

Arm D
(n=40-60)

        Received emicizumab prophylaxis at 3mg/kg by once-weekly subcutaneous injection for 4 weeks, followed by 1.5 mg/kg once-weekly subcutaneous injection
 

Episodic treatment of breakthrough bleeds with factor VIII therapy was allowed per protocol.

About emicizumab clinical development status

In addition to the HAVEN 1, HAVEN 2 and HAVEN 3 studies, a global phase lll HAVEN 4 study (NCT03020160) is currently underway by Chugai, Roche and Genentech to evaluate emicizumab prophylaxis once every four weeks by subcutaneous injection in hemophilia A patients with or without factor VIII inhibitors.

About Chugai

Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals, and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2016 of Chugai totaled 491.8 billion yen and the operating income was 80.6 billion yen (IFRS Core basis).
Additional information is available on the internet at https://www.chugai-pharm.co.jp/english.

 

References

1)   Kitazawa, et al. Nature Medicine 2012; 18(10): 1570
2) Sampei, et al. PLoS ONE 2013; 8: e57479

Contact information

For Media
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
Koki Harada
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp
***
For US media
Chugai Pharma USA Inc.
Paul Mignone
Tel: +1-908-516-1350
E-mail: pr@chugai-pharm.com
***
For European media
Chugai Pharma France SAS
Nathalie Leroy
Tel: +33-1-56-37-05-21
E-mail: pr@chugai.eu
***
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Susan Chou, Osamu Kagawa
Tel: +886-2-2715-2000
E-mail: pr@chugai.com.tw
***
For Investors
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel: +81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Keio Plaza Hotel Tokyo Hosts "Princess Mermaid Sweets Buffet"21.6.2018 14:05Pressemelding

Keio Plaza Hotel Tokyo (KPH), one of Japan’s most prestigious international hotels located in Shinjuku, Tokyo, will host the “Princess Mermaid Sweets Buffet” in commemoration of the fairy tale written by the Danish author Hans Christian Andersen at our All Day Dining Restaurant “Jurin” from July 1 (Sunday) to September 30 (Sunday), 2018. This year’s buffet will offer a wide range of colorful desserts based on the “deep blue color of the cornflower” and other various flowers specially prepared by our patissiers and patterned after various sea creatures reminiscent of characters portrayed in the Little Mermaid fairy tale. Some of delectable desserts include clams made of chocolate and “deep sea mousse” made in a colorful blue using passion fruit and pineapple flavorings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180621005383/en/ A wide range of colorful desserts based on the deep blue color and patterned after various sea

Clearhaus gir norske nettbutikker Apple Pay 21.6.2018 13:35Pressemelding

Apples mobilbetalingstjeneste, Apple Pay, har nettopp blitt lansert i Norge. Banker som Santander og Nordea er de første som introduserer tjenesten til norske forbrukere. Samtidig sørger den danske innløsningsvirksomheten Clearhaus for å gjøre den innovative, nye betalingsmetoden tilgjengelig i norske nettbutikker. Mobillommebok-teknologi som Apple Pay endrer hvordan folk kjøper og selger varer i butikker, i apper og på nettet. Apple Pay drives av Visa- og Mastercards tokeniseringsteknologi. Tjenesten gjør det mulig for iPhone-, Apple Watch-, iPad- og Mac-brukere å betale for varer på en enkel og sikker måte. Ved bruk av Apple Pay på nettet, trenger ikke forbrukere lenger å taste inn 16 kreditt- eller debetkortsiffer, utløpsdatoer og sikkerhetskoder. Etter å ha gjennomført et enkelt engangsoppsett med et kreditt- eller debetkort, kan brukere enkelt foreta kjøp i fysiske butikker eller i nettbutikker. Dette gjøres ved å plassere fingeren på touch id-platen eller ved å bruke ansiktsgjenk

Wipro Positioned as a Leader in Gartner’s Magic Quadrant 2018 for Oracle Application Services, Worldwide21.6.2018 13:22Pressemelding

Wipro Limited (NYSE: WIT) (BSE: 507685) (NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has been positioned as a Leader in Gartner’s Magic Quadrant 2018 for Oracle Application Services, Worldwide. The report authored by Alan H Stanley, Susanne Matson, Jim Longwood and Allan Wilkins was published on February 28, 2018. This Magic Quadrant is focused on the full life-cycle of Oracle application services, spanning across project-based implementation and multi-year application management services (AMS). The report evaluated 19 service providers from across the globe and placed Wipro in the Leaders quadrant. Wipro is positioned the highest for its ‘ability to execute’ among all service providers. Please click here to view the complete Magic Quadrant report for Oracle Application Services 2018, Worldwide. Additionally, Wipro has been positioned in the Top 3 for three use cases namely, Implementation services, Man

Seoul Semiconductor Captures the Home Lighting Market with Its Innovative LED SunLike Technology21.6.2018 13:00Pressemelding

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a market leader in LED (light emitting diode) design and manufacturing, has launched into the global home lighting market with its innovative LED technology “SunLike.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180621005553/en/ Seoul Semiconductor, a market leader in LED design and manufacturing, launched into the global home lighting market with its innovative LED technology SunLike. SunLike implementing a spectrum similar to sunlight by lowering the blue light wavelength compared to an ordinary LED. (Graphic: Business Wire) Seoul Semiconductor announced that Mimi Lighting, a Korean LED lighting company, applied an innovative technology SunLike to the company’s home lighting products, which to be launched in the 3Q. SunLike applied to this home lighting is a natural light LED, which minimizes the disadvantages of artificial lighting and maximizes the advantages of natural l

MYbank Launches Star Plan to Support 1,000 Financial Institutions to Serve 30 Million SMEs in the Next Three Years21.6.2018 12:56Pressemelding

MYbank, a leading online private commercial bank in China with a focus on SME financing, today announced the launch of the Star Plan to open up its proven AI, computing and risk management capabilities to financial institutions in China. Through sharing these technological capabilities, MYbank aims to enable 1,000 financial institutions to provide more cost-effective financing services to 30 million SMEs and farmers in China in the next three years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180621005666/en/ Announcing the launch of the Star Plan at the 2018 SME Financing Summit in Hangzhou, Eric Jing, Chairman of MYbank, Executive Chairman and CEO of Ant Financial, said, “The widespread application of advanced technologies in the SME financing space has dramatically improved risk management and lowered costs. With these innovations, we can unlock new opportunities for financial institutions and enable them to sustainabl

IFA 2018 : LG CEO and CTO to Outline Ambitious Strategy for ThinQ AI at IFA Opening Keynote21.6.2018 12:28Pressemelding

LG Electronics (LG) Chief Executive Officer Jo Seong-Jin and Chief Technology Officer Dr. I.P. Park will deliver a joint opening keynote at IFA 2018 to outline their vision for LG’s ThinQ strategy for Artificial Intelligence. The first IFA keynote for both executives, titled Think Wise, Be Free: Living Freer with AI will be delivered on Friday, August 31, in Hall 26b at Messe Berlin. With interest in all things AI at a peak, CEO Jo will provide his insight into how LG’s AI strategy will change customers’ lives based on its unique philosophy of an “open platform, open partnership and open connectivity”. Dr. Park will show how this technology comes to life in everyday products like refrigerators, TVs and washing machines, and how LG’s open AI strategy benefits consumers thanks to its focus of giving them both control and convenience. “The IFA Keynotes provide CEOs and top executives with a global media platform for forward thinking ideas and strategies,” said Jens Heithecker, Messe Berli